Imatinib mesylate for melanoma: Will a new target be revealed?

Journal of Investigative Dermatology

Volumn 123, Issue 6, 2004, Pages

  Grossman, Douglas ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTOTOXIC AGENT; ETANERCEPT; IMATINIB; IMIQUIMOD; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPEREOSINOPHILIC SYNDROME; KELOID; MELANOMA; MELANOMA CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 9744285768     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23526.x     Document Type: Note

References (14)

1. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG: The FIP1L1-PDGFR-alpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 11:51-57, 2004
2. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830, 1990
3. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185, 2003
4. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
5. Easty DJ, Herlyn M, Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60:129-136, 1995
6. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH: Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577-1578, 2002
7. Goffe B, Cather JC: Etanercept: An overview. J Am Acad Dermatol 49:S105-S111, 2003
8. Halaban R: The regulation of normal melanocyte proliferation. Pigment Cell Res 13:4-14, 2000
9. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
10. McGary EC, Onn A, Mills L, et al: Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 122:400-405, 2004
11. Noonan FP, Recio JA, Takayama H, et al: Neonatal sunburn and melanoma in mice. Nature 413:271-272, 2001
12. Redondo P, Lloret P, Andreu E, Inoges S: Imatinib mesylate in cutaneous melanoma. J Invest Dermatol 123:1208-1209, 2004
13. Shen SS, Zhang PS, Eton O, Prieto VG: Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30:539-547, 2003
14. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001